JMB-HEADER NAUKA RAS RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 51(2017) N 6 p. 921-926; DOI 10.1134/S0026893317060061 Full Text

G.A. Efimov1,2,3, J.M.H. Raats4, R.G.S. Chirivi4, J.W.G. van Rosmalen4, S.A. Nedospasov2,3,5*

Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story

1National Research Center for Hematology, Ministry of Healthcare of the Russian Federation, Moscow, 125167 Russia
2Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia
3Moscow State University, Moscow, 119991 Russia
4ModiQuest B.V., 5349 AE Oss The Netherlands
5Lobachevsky University of Nizhny Novgorod, Nizhny Novgorod, 603022 Russia

*sergei.nedospasov@gmail.com
Received - 2017-06-20; Accepted - 2017-07-21

Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab.

TNF, tumor necrosis factor, recombinant antibodies, humanized antibodies



JMB-FOOTER RAS-JOURNALS